Novartis is falling farther behind AbbVie, which expanded its JAK inhibitor Rinvoq into giant cell arteritis in April.

Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are ...

While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing ...

An open letter signed by more than 50 industry executives blasts a “fundamentally, fatally flawed” report that urges greater ...

Why did two private equity firms with more than $460 billion under management want a little old gene therapy biotech called ...

As an office of the executive branch, the Department of Health and Human Services “does not have the authority” to implement ...

The safety update for Vyvgart rattled argenx’s shares on Monday, a reaction that analysts at William Blair said was “overdone ...

Kennedy wants to expand the injury compensation program to include COVID-19 vaccines, while also stretching the “statute of ...

Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say ...

The women’s health focused company acquired the drug for up to $954 million in 2021 through the acquisition of Forendo Pharma.

California’s life sciences manufacturing jobs dipped 3.7% in 2024, according to a new Biocom California report. Still, ...

Protagonist is directly going up against Eli Lilly, which is advancing retatrutide, also a triple-G agonist, in a Phase II ...